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Introduction
Neoadjuvant radiochemotherapy (RCT) followed by total mesorectal excision (TME) has become standard treatment in locally advanced UICC (Union International contre le Cancer) II/III rectal cancer within the last decade (1) . Individual treatment response, however, varies considerably. As shown in our previous studies, histopathological tumor regression ranges from a complete response with no viable tumor cells detectable to virtually no regression at all (2) . Despite uniform treatment protocols, this observed variance in tumor response is most probably caused by differences in the genetic profile expressed in the individual lesions (3, 4) , and might influence long-term survival (5) . Reliable molecular markers may help to individually tailor multimodal treatment regimens by risk-adapted or novel therapeutic approaches.
Survivin, the smallest member of the inhibitor-of-apoptosis (IAP) family is a multifunctional protein that is reported to interact at the crossroads of disparate molecular networks of cellular division, intracellular signaling and apoptosis (6, 7) . In this context, one of the signature features of survivin is not only its ability to associate with multiple protein partners, but also to localize to disparate subcellular compartments (8, 9) . Abundantly over-expressed in nearly every tumor tested so far, survivin is associated with a more aggressive tumor behavior and worse clinical outcome (10) . In addition, survivin is involved in resistance to both chemotherapy and ionizing irradiation (11) . Several preclinical in vitro studies have demonstrated that targeting survivin's expression by the use of small interfering RNAs, antisenseoligonucleotides and small molecule repressors radiosensitize tumor cells and reduces tumor growth in vivo. Due to these properties, survivin has been proposed as a molecular target for anticancer therapies (12, 13) .
Although the role of survivin as a prognostic marker is consistent within the literature, its value as a marker for the prediction of treatment response towards radiation therapy or RCT remains controversial (14) . In rectal cancer, a high survivin RCT or short-course radiotherapy was significantly associated with a higher risk of local tumor recurrences (15) and decreased survival (16) , respectively. However, other studies with smaller and more heterogeneous patient cohorts reported that there were no correlations between survivin mRNA or protein expression and histopathological tumor regression grades as well as clinical outcome (17, 18) . This discrepancy may in part arise from the use of different methods of survivin evaluation, the use of different clinical endpoints or different quantitative scoring systems of the expression characteristics as well as variable stratification of the patient groups.
Recent data indicate that in oesophageal and ovarian cancer intratumoral survivin expression decreased significantly during neoadjuvant chemotherapy or RCT (19, 20) . In contrast, elevated postoperative survivin levels after neoadjuvant treatment were significantly associated with a higher tumor stage, poor histopathological response, and reduced cancer-specific survival.
In the present study, survivin expression was -for the first time -evaluated in both pre-treatment biopsies and corresponding surgical specimens from patients with locally advanced rectal cancer, treated with standardized preoperative RCT within randomized clinical phase III trials. Methodical and inter-observer accordance were evaluated between two independent institutions, and survivin expression levels were correlated with clinicopathologic characteristics and clinical follow-up.
Research. 
Immunohistochemical staining of survivin
Immunhistochemical staining of survivin was performed on rectal cancer biopsies and on the corresponding surgical specimens. In 11 patients (9.5%) with pathologically confirmed complete response (pCR) after neoadjuvant RCT staining for survivin was only accessible on the pre-treatment biopsies. 
Statistical Methods
Statistical analysis was performed using the open-source statistical computing software R and the packages exactRankTests and survival. Correlation of the survivin labeling score with clinical outcome variables was computed by the Spearman Rank correlation using the function cor.test. Two group comparisons were performed using a Wilcoxon Rank Test. Time to event data were visualized using Kaplan-Meyer analysis and significance was computed based on Cox proportional hazards regression models using the function coxph when using the ordinal survivin score (0 to 12) or based on a log Rank test using the function survdiff when using the dichotomized survivin score. Additionally, the influence on the following variables:
gender, age, TRG, ypT, ypN and ypUICC-stage on survival was assessed in univariate analysis, since of these variables only gender and ypN reached significance, multivariate analysis was done using these variables and post-treatment survivin score in a Cox model. The level of significance was set to α=5% for all tests.
Research.
on 
Results

Clinical characteristics
Clinical staging results of all 116 patients are presented in Table 1 . Therapy-and surgery-related 30-day morbidity and mortality were 22% and 0%, respectively. In initial staging 85 patients (73%) had evidence of mesorectal lymph node involvement (cN+). After preoperative RCT, 44 patients (38%) presented with residual nodal metastases (ypN+). Within the follow-up period, cancer relapse occurred in 26 patients (22%). Isolated distant metastatic disease occurred in 22 patients (19%)
whereas simultaneous local and distant recurrence was observed in an additional 4 patients (3%). There was no case of isolated local cancer recurrence. Cancer-related death within the follow-up period occurred in 13 patients (11%). Pathologic staging results and tumor recurrences are summarized in Table 1 . 
Immunostaining of survivin on pre-treatment biopsies and surgical resections
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Downregulation of survivin expression following neoadjuvant radiochemotherapy
As compared to pre-therapeutic biopsies, a highly significant down-regulation of survivin expression (p < 0.0001) was observed after neoadjuvant RCT (Figure 2A ). In patients with a down-regulation of survivin during preoperative RCT, a significant decrease of distant cancer relapse (p=0.022) was observed. Moreover, a significant correlation between high survivin expression levels in residual tumor after RCT and shortened DFS (p=0.011) ( Figure 3A ) as well as CSS (p=0.0017) ( Figure 3B ) was evident. In multivariate analyses intratumoral survivin expression was confirmed as an independent prognostic factor with significant influence on DFS (p=0.02) and CSS (p=0.01) ( Table 3 ).
Discussion
In the present study, we investigated the predictive and prognostic relevance of survivin expression both in pre-treatment biopsies and corresponding surgical specimens of 116 patients with locally advanced rectal cancer treated with standardized 5-FU based neoadjuvant RCT. Comparing pre-treatment biopsies and surgical resection specimens we observed a significant down-regulation of survivin in cancer cells following RCT (Figure 2 ). This finding is in line with a significant downregulation of survivin expression, as recently described in ovarian and oesophageal cancer treated with neoadjuvant chemotherapy or RCT (19, 20) . In the latter study, patients with elevated survivin score after RCT and deficient down-regulation were reported to have minor histomorphological tumor regression and decreased survival rates.
In our present investigation, a low survivin expression in pre-treatment biopsies was significantly related to lower tumor (ypT) and ypUICC stages after preoperative RCT.
As these parameters display strong prognostic factors in recent investigations (2, 24), survivin expression is assumed to be not only a predictive marker for local tumor control but also for disease-free survival after preoperative RCT and surgical resection. The predictive relevance of survivin expression in rectal cancer, however, is controversial as conflicting data exist concerning the relationship between survivin expression and response to RCT. Most investigations, including our own previous studies, reported a significant association between a low survivin expression in pretreatment biopsies and decreased distant and local recurrence rates as well as increased survival (15, 16) . While our present results further strengthens a predictive value of pre-treatment survivin levels for patients treated with neoadjuvant RCT, other studies with smaller study cohorts did not report on any relevance of intratumoral survivin expression (17, 18) . 
